Characterization of Multisystem Inflammatory Syndrome in Children (MIS-C) and Its Relationship to Kawasaki Disease
NCT ID: NCT04538495
Last Updated: 2025-08-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
268 participants
OBSERVATIONAL
2020-08-01
2022-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
COVID-19 and Multisystem Inflammatory Syndrome in Children (MIS-C) Risk / World Health Organization (WHO)
NCT06255860
COVID-19: Immunological Mechanisms in Multisystem Inflammatory Syndrome in Children
NCT05334134
MultiOrgan Inflammatory Syndromes COVID-19 Related Study
NCT04811456
Epidemiologic Features of Kawasaki Disease in Shanghai From 2008 Through 2012
NCT02317913
Epidemiologic Features of Kawasaki Disease in Shanghai From 2013 Through 2017
NCT03880929
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Parent observations (Kim): To learn about signs and symptoms in the patient and family members leading up to acute presentation a parent questionnaire will be devised and analyzed by Dr. Katherine Kim with the Patient and Parent Advisory Board. The investigators will collect known signs and symptoms as well as those that may not have been previously reported in the literature and record presence/absence, location in the body, and severity level by day. The questionnaire will be available as a mobile/web application and via paper. With these data, the investigators will conduct an exploratory analysis to characterize symptom phenotypes and the relationships of these profiles with demographic features and clinical characteristics. In addition, the investigators will assess whether we can detect differences between the symptom phenotypes of KD and MIS-C. The investigators will conduct cluster analysis to identify symptom phenotypes from aggregate symptom observations blinded as to presumed or verified diagnosis (n=100 with each sign/symptom on each day as a distinct data point). Phenotypes may include characteristics such as symptoms that co-occur or are independent, and symptom burden index (e.g., number symptoms present). The investigators will use Ward's hierarchical cluster analysis to estimate the number of likely clusters.3 The investigators will apply K-means nonhierarchical cluster analysis repeated 100 times in a leave-one out validation model to assure repeatability and stability within the model. The investigators will create score indices analyzed with logistic regression, principal component analysis, factor analysis and correlation analysis. The investigators will then assess whether clusters are related to verified diagnosis and/or sociodemographic characteristics such as age, race/ethnicity, geography. The investigators will use discriminant analysis techniques and more recent classification techniques such as CART to examine if symptom phenotypes of KD and MIS-C are dissimilar. If information in terms of symptom clusters at a point in time or a trajectory of a single symptom over time are insufficient to distinguish between the two conditions, this would provide support for the argument that the recorded symptoms are insufficient for discrimination or that the two disease entities are not symptomatically different. This exploratory analysis will provide important information that can be further developed for clinical guidance and parent education.
Photography (Kim, Tremoulet): Patient photographs of the eye, mouth/tongue, and rash will be collected as a novel addition to the usual clinical data. These photographs obtained before treatment will document the presence or absence of conjunctival injection and perilimbal sparing, mucocutaneous changes in the oropharynx including changes in the vermillion border (erythema, fissuring) and the tongue (strawberry tongue), and the nature of the rash. The photographs will be subjected to analysis using facial recognition software and artificial intelligence approaches used by our collaborators at the University of Southern California Center for Artificial Intelligence in Society led by Hayden Shively and Lucas Hu to evaluate whether a computer algorithm can be created that can differentiate the clinical characteristics of MIS-C from photographs taken of children with acute KD and those with other pediatric febrile illnesses. Dr. Katherine Kim at UC Davis will compare the photos with the questionnaire responses to supplement the parent descriptions of signs and symptoms and validate the observations. This comparison can result in enhanced descriptions using the words of parents themselves. Photography is needed to document these physical findings as the investigators have learned over the years that physician description of these features is woefully inaccurate. The finding, for example, of a strawberry tongue is a specific injury pattern that involves sloughing of the cornified tips of the filiform papillae and has historically been associated with only 3 conditions: staphylococcal and streptococcal toxin-mediated disease and KD.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Patients who meet the CDC definition for MIS-C:
* Patients presenting with fever (\>38C for \>24 h - also by subjective report), laboratory evidence of inflammation, and evidence of clinically severe illness requiring hospitalization, with multisystem (\>2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic or neurological); AND
* No alternative plausible diagnoses; AND Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test; or suspected COVID-19 exposure within the 4 weeks prior to the onset of symptoms
* Patients who meet the CDC definition for MIS-C and require care in the PICU
Exclusion Criteria
1 Month
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, San Diego
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jane C. Burns MD
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jane C Burns
Role: PRINCIPAL_INVESTIGATOR
University of California, San Diego
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California, San Diego
La Jolla, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CER-1602-34473
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.